US8340749B2 - System for automatically minimizing cardiac oxygen consumption and cardiac disease treating system using the same - Google Patents
System for automatically minimizing cardiac oxygen consumption and cardiac disease treating system using the same Download PDFInfo
- Publication number
- US8340749B2 US8340749B2 US12/279,753 US27975307A US8340749B2 US 8340749 B2 US8340749 B2 US 8340749B2 US 27975307 A US27975307 A US 27975307A US 8340749 B2 US8340749 B2 US 8340749B2
- Authority
- US
- United States
- Prior art keywords
- value
- cardiac
- pressure
- oxygen consumption
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related, expires
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/021—Measuring pressure in heart or blood vessels
- A61B5/0215—Measuring pressure in heart or blood vessels by means inserted into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/026—Measuring blood flow
- A61B5/029—Measuring or recording blood output from the heart, e.g. minute volume
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4866—Evaluating metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/362—Heart stimulators
- A61N1/365—Heart stimulators controlled by a physiological parameter, e.g. heart potential
- A61N1/36514—Heart stimulators controlled by a physiological parameter, e.g. heart potential controlled by a physiological quantity other than heart potential, e.g. blood pressure
- A61N1/36557—Heart stimulators controlled by a physiological parameter, e.g. heart potential controlled by a physiological quantity other than heart potential, e.g. blood pressure controlled by chemical substances in blood
Definitions
- This invention relates to a system for automatically minimizing the amount of cardiac oxygen consumption that is capable of estimating the amount of a patient's cardiac oxygen consumption with high accuracy and moreover minimizing the amount of cardiac oxygen consumption and a cardiac disease treating system using the same.
- cardiac a medicine supposed to stimulate the heart
- cardiopathy as the therapy for improving such kinetics of blood circulation as blood pressure, cardiac output, and pressure of left atrium.
- vasodilator possibly entails hypotension in case of excess dosage and the ⁇ blocking agent simultaneously entails bradycardia and depression of ventricular contractility, they have proved to be contraindications for the sake of a case of serious cardiac failure.
- the administration of the ⁇ blocking agent must be implemented by a specialist who is thoroughly versed in the efficacy of this medicine and cannot be performed easily by a physician who is not a specialist.
- the conventional therapy has not been established as a proper treatment appropriate to the amount of cardiac oxygen consumption because it has not estimated the amount of cardiac oxygen consumption even quantitatively or semi-quantitatively.
- it has possibly occasioned either administration of varying medicines in larger doses than necessary or administration of varying medicines for longer periods than necessary and has consequently incurred the problem that the possibility of inducing side effects of such medicines will be enhanced and the cost of therapy will be increased.
- This invention has been initiated with a view to solving the problem mentioned above and is aimed at providing a system for automatically minimizing the amount of cardiac oxygen consumption that is capable of estimating the amount of a patient's cardiac oxygen consumption with high accuracy and moreover minimizing the amount of cardiac oxygen consumption and a cardiac disease treating system using the same.
- This invention is also aimed at providing a system for automatically minimizing the amount of cardiac oxygen consumption that is capable of avoiding side effects caused by medicines and increase of cost of therapy and enabling even a nonspecialized physician to minimize the amount of cardiac oxygen consumption easily and a cardiac disease treating system using the same.
- This invention has solved the problem mentioned above by the following means.
- a system for automatically minimizing cardiac oxygen consumption comprises:
- a cardiac oxygen consumption calculation part for calculating the estimated value of the patient's amount of cardiac oxygen consumption based on the indexes of kinetics of circulation input from the input part
- a cardiac oxygen consumption curtailment part for comparing the heart rate input from the input part and the critical heart rate minimizing the estimated value of amount of cardiac oxygen consumption calculated by the cardiac oxygen consumption calculation part and controlling the patient's heart rate in conformity with the results of this comparison.
- a system for automatically minimizing cardiac oxygen consumption according to the first non-limiting embodiment is modified, so that the indexes of kinetics of circulation further include the value of blood pressure, value of cardiac output, value of pressure of left atrium, and value of pressure of right atrium and the cardiac oxygen consumption calculation part calculates the value of function of systemic heart by using the following numerical formula (1) from the value of cardiac output and the value of pressure of left atrium, calculates the value of blood vessel resistance by using the following numerical formula (2) from the value of blood pressure, the value of pressure of right atrium, and the value of cardiac output, calculates the slope of end-systolic pressure-volume relation by using the following numerical formula (3) from the value of function of systemic heart, the value of blood vessel resistance, and the heart rate, calculates the pressure-volume area by using the following numerical formula (4) from the value of blood pressure, the value of pressure of left atrium, the value of cardiac output, and the heart rate, and calculates the estimated value of amount of cardiac oxygen consumption by using the following numerical formula (1) from the value of cardiac output and the
- a system for automatically minimizing cardiac oxygen consumption according to the first non-limiting embodiment or the second non-limiting embodiment are modified, so that the cardiac oxygen consumption curtailment part controls the patient's heart rate by administering a medicine to the patient.
- a system for automatically minimizing cardiac oxygen consumption according to the third non-limiting embodiment is modified, so that the cardiac oxygen consumption curtailment part controls the spontaneous activity of sinus node by administering to the patient a medicine for lowering the heart rate at the time of starting treatment and additionally administering the medicine for lowering the heart rate when the spontaneous activity appears.
- a system for automatically minimizing cardiac oxygen consumption according to the fourth non-limiting embodiment is modified, so that the medicine is a ⁇ blocking agent, a calcium antagonist, or a specific bradycardic agent.
- a system for automatically minimizing cardiac oxygen consumption according to any of the first, second, third, fourth and fifth non-limiting embodiments is modified, so that the cardiac oxygen consumption curtailment part controls the heart rate of the patient by imparting electrical stimulation to the patient.
- a system for automatically minimizing cardiac oxygen consumption according to any of the first, second, third, fourth, fifth, and sixth non-limiting embodiments is modified, so that it further comprises: a display means for continuously displaying in time series the indexes of a patient's kinetics of circulation.
- a system for automatically minimizing cardiac oxygen consumption according to any of the first, second, third, fourth, fifth, sixth, and seventh non-limiting embodiments is modified, so that the value of cardiac output is measured with a Swan-Ganz catheter or calculated from the diastolic time constant of arterial blood pressure waveform.
- a system for automatically minimizing cardiac oxygen consumption according to any of the first, second, third, fourth, fifth, sixth, seventh and eighth non-limiting embodiments is modified, so that the value of pressure of left atrium is directly measured with a catheter or calculated by being continuously estimated from the pulmonary wedge pressure with a Swan-Ganz catheter or the value of pulmonary pressure during the diastolic period.
- a cardiac disease treating system that comprises:
- A a system for automatically minimizing cardiac oxygen consumption according to any of the first, second, third, fourth, fifth, sixth, seventh, eighth and ninth non-limiting embodiments
- B a first calculation means for calculating the value of cardiac function from the value of cardiac output, the value of pressure of right atrium, and the value of pressure of left atrium input from the input part
- C a first comparison means for comparing the value of cardiac function calculated by the first calculation means and the target value of cardiac function
- D a first administration means for administering a medicine to the patient in conformity with the result of the comparison effected by the first comparison means.
- a cardiac disease treating system according to the tenth non-limiting embodiment is modified to further comprise:
- a cardiac disease treating system according to the tenth non-limiting embodiment or the eleventh non-limiting embodiment are further modified to: a third calculation means for calculating the value of blood vessel resistance from the value of cardiac output, the value of pressure of right atrium, and the value of blood pressure input from the input part, a third comparison means for comparing the value of blood vessel resistance calculated by the third calculation means and the target value of blood vessel resistance, and a third administration means for administering a medicine to the patient in conformity with the results of the comparison effected by the third comparison means.
- the part for curtailing the amount of cardiac oxygen consumption mentioned above is enabled to control the heart rate of a patient by a method of administering a medicine to the patient and/or imparting an electrical stimulation to the patient, this method is capable of controlling the patient's heart rate rapidly and easily in spite of procedural simplicity.
- the indexes of a patient's kinetics of blood circulation mentioned above further include the value of blood pressure, value of cardiac output, value of pressure of left atrium, and value of pressure of right atrium.
- the estimated value of the amount of cardiac oxygen consumption can be rapidly worked out by a simple operation when the part that calculates the amount of cardiac oxygen consumption mentioned above calculates the value of the systemic heart function from the value of amount of cardiac output mentioned above and the value of the pressure of the left atrium mentioned above by using the aforementioned numerical formula (1), the value of blood vessel resistance from the value of the blood pressure mentioned above, the value of the pressure of the right atrium mentioned above, and the value of the cardiac output mentioned above by using the aforementioned numerical formula (2), the slope of end-systolic pressure-volume relation from the value of the systemic heart function mentioned above, the value of the blood vessel resistance mentioned above, and the value of the heart rate mentioned above by using the aforementioned numerical formula (3), the pressure-volume area from the value of blood pressure mentioned above, the value of the pressure of the left atrium
- the part that manages curtailment of the cardiac oxygen consumption mentioned above enables the heart rate of a patient to be efficiently lowered by administering a medicine capable of lowering the heart rate on the patient at the start of therapy thereby inhibiting the spontaneous activity of the sinus node and, when the spontaneous activity appears, additionally administering the bradycardic agent mentioned above.
- a display means capable of continuously displaying the aforementioned indexes of a patient's kinetics of blood circulation is additionally incorporated, it enables the patient to be infallibly diagnosed without any fear of overlooking time series changes of such numerical values as blood pressure and as well the transition of the patient's condition brought about by the therapy in the form of administration to be displayed.
- a cardiac disease treating system is composed of the system of this invention for automatically minimizing cardiac oxygen consumption, a first calculation means for calculating the value of cardiac function from the value of the cardiac output mentioned above, the value of the pressure of right atrium mentioned above, and the value of the pressure of left atrium mentioned above input from the input part mentioned above, a first comparison means for comparing the value of cardiac function mentioned above calculated by the first calculation means mentioned above with the target value of cardiac function, and a first administration means for effecting administration of a medicine to the patient in conformity with the results of comparison obtained by the first comparison means mentioned above, it is capable of infallibly and accurately normalizing the abnormality of the patient's cardiac function while minimizing the amount of cardiac oxygen consumption because it compares the values of left and right cardiac functions with the target value of cardiac function and effects the administration of a medicine in conformity with the results of the comparison.
- the cardiac disease treating system mentioned above is further furnished with a second calculation means for calculation the value of the amount of effectively circulated blood from the value of the cardiac output mentioned above, the value of the pressure of left atrium mentioned above, and the value of the pressure of right atrium mentioned above, a second comparison means for comparing the value of the amount of effectively circulated blood calculated by the second calculation means mentioned above with the value of the target amount of effectively circulated blood, and a second administration means for effecting administration of a medicine to the patient in conformity with the results of the comparison obtained by the second comparison means mentioned above, it is capable of infallibly and accurately normalizing the abnormality of the patient's amount of effectively circulated blood while minimizing the amount of cardiac oxygen consumption because it compares the value of the amount of effectively circulated blood found by calculation with the target value of the amount of effectively circulated blood and effects the administration of a medicine in accordance with the results of the comparison.
- a third calculation means for calculating the value of blood vessel resistance from the value of the amount of cardiac output mentioned above entered from the input part mentioned, the value of the pressure of right atrium mentioned above, and the value of blood pressure mentioned above
- a third comparison means for comparing the value of blood vessel resistance mentioned above calculated by the third calculation means mentioned above with the value of target blood vessel resistance
- a third administration means for effecting administration of a medicine to the patient in conformity with the results of comparison obtained by the third comparison means mentioned above, it is capable of infallibly and accurately normalizing the value of the patient's blood vessel resistance while minimizing the amount of cardiac oxygen consumption because it compares the value of blood vessel resistance found by calculation with the value of target blood vessel resistance and effects the administration of a medicine in accordance with the results of the comparison.
- the cure results in infallibly and accurately normalizing the patient's value of blood pressure, amount of cardiac output, and value of pressure of left atrium while minimizing his amount of cardiac oxygen consumption.
- FIG. 1 This is a schematic diagram of the cardiac disease treating system according to a mode of embodying this invention.
- FIG. 2 This is a schematic diagram of a heart.
- FIG. 3 This is a schematic diagram illustrating the relation of the input part and the cardiac oxygen consumption monitor unit in the cardiac disease treating system according to the present mode of embodiment.
- FIG. 4 This is a graph showing the estimated values of amount of cardiac oxygen consumption and the actually measured values of amount of cardiac oxygen consumption in dogs calculated by using the cardiac oxygen consumption monitor unit according to the present mode of embodiment.
- FIG. 5 This is a schematic diagram illustrating the relation of the input part and the cardiac oxygen consumption curtailment unit in the cardiac disease treating system according to the present mode of embodiment.
- FIG. 6 This is a graph showing the relation of the slope of end-systolic pressure-volume relation (Ees) and the heart rate.
- FIG. 7 This is a graph showing the relation of the amount of cardiac oxygen consumption (VO 2 ) and the heart rate.
- FIG. 8 This is a schematic diagram of the cardiac disease treating unit according to the present mode of embodiment.
- FIG. 9 This is a graph showing the results of an experiment performed by using the cardiac disease treating system according to the present mode of embodiment.
- FIG. 10 This is a graph showing the relation of the actually measured value of amount of cardiac oxygen consumption and the heart rate obtained in the experiment.
- FIG. 11 This is a graph showing the estimated values of amount of cardiac oxygen consumption and the actually measured values of amount of cardiac oxygen consumption in dogs calculated by using the cardiac oxygen consumption monitor unit in the experiment.
- FIG. 1 is a schematic diagram of the cardiac disease treating system according to the present mode of embodiment.
- FIG. 2 is a schematic diagram of a heart.
- a cardiac disease treating system 10 according to the present mode of embodiment utilizes a value of cardiac output, a value of pressure of left atrium, and a value of pressure of right atrium that are shown in FIG. 2 and a value of blood pressure and a heart rate that are not shown in FIG. 2 .
- the cardiac disease treating system 10 is composed of an input part 12 , a cardiac oxygen consumption monitor unit 14 (“part for calculating the amount of cardiac oxygen consumption” according to this invention), a cardiac oxygen consumption curtailment unit 16 (“part for curtailing the amount of cardiac oxygen consumption” according to this invention), and a cardiac disease treating unit 18 .
- the input part 12 is intended to input the indexes of the kinetic of blood circulation of a patient 20 that include the value of blood pressure, value of cardiac output, value of pressure of left atrium, value of pressure of right atrium, and heart rate.
- the input part 12 is not particularly restricted but is only required to be capable of outputting the numerical data of the indexes of the kinetic of blood circulation of the patient 20 to the cardiac oxygen consumption monitor unit 14 , cardiac oxygen consumption curtailment unit 16 , and cardiac disease treating unit 18 as described herein below. Therefore, the input device such as a keyboard that is used by the user of the cardiac disease treating system 10 in inputting such numerical data as the value of blood pressure which has been actually measured may be employed or the measuring device (such as, for example, a blood-pressure meter) for measuring the kinetic of blood circulation of the patient 20 and directly outputting the resultant numerical data may be employed, for example.
- the input device such as a keyboard that is used by the user of the cardiac disease treating system 10 in inputting such numerical data as the value of blood pressure which has been actually measured may be employed or the measuring device (such as, for example, a blood-pressure meter) for measuring the kinetic of blood circulation of the patient 20 and directly outputting the resultant numerical data may be employed, for example.
- the measuring device that measures the kinetics of blood circulation of the patient 20 and directly outputs the numerical data of the kinetics of blood circulation.
- FIG. 3 is a schematic diagram showing the relation between the input part 12 and the cardiac oxygen consumption monitor unit 14 in the cardiac disease treating system according to the present mode of embodiment.
- the input part 12 in the present mode of embodiment is composed of a Swan-Ganz catheter 12 A for measuring the value of cardiac output, value of pressure of left atrium, and value of pressure of right atrium of the patient, a blood pressure catheter 12 B for measuring the value of blood pressure, and an electrocardiogram 12 C for measuring the heart rate.
- the value of blood pressure, value of cardiac output, value of pressure of left atrium, value of pressure of right atrium, and heart rate can be severally measured with heretofore known measuring devices and do not need to be limited to the example cited in the present mode of embodiment.
- the input part 12 for the purpose of furnishing the patient with continuous diagnosis measures and uses continuously the numerical data of the value of blood pressure, value of cardiac output, value of pressure of left atrium, value of pressure of right atrium, and heart rate.
- the present mode of embodiment therefore, adopts a method of continuously estimating the value of pressure of left atrium by continuously estimating it from the value of diastole of the pulmonary pressure (the value of pulmonary pressure during diastole) and utilizing the result as a continuous numerical data.
- this value of pressure of left atrium is known to possess a linear relation with the value of pulmonary pressure during diastole, the value of pressure of left atrium can be calculated from the value of pulmonary pressure during diastole based on the average correlation among multiple individuals.
- the value of pressure of left atrium is calculated by utilizing this value of pulmonary pressure during diastole, it is preferable to have the average correlation among multiple individuals readied for compensation with the heart rate because the correlation (linear relation) between the value of diastolic pulmonary pressure and the value of pressure of left atrium varies in accordance as the heart rate varies.
- the value of cardiac output can be utilized as a continuous numerical data by adopting a method of estimating this value from the diastolic time constant of the waveform of peripheral blood pressure.
- the system to be provided is enabled to acquire extremely high accuracy.
- the cardiac oxygen consumption monitor unit 14 in the present mode of embodiment is formed of a computer and adapted to calculate the estimated value of cardiac oxygen consumption of the patient 20 based on the indexes of kinetic blood circulation (the value of blood pressure, value of cardiac output, value of pressure of left atrium, value of pressure of right atrium, and heart rate in the present mode of embodiment) input from the input part 12 via an amplifier 22 .
- the amplifier 22 is not necessary when the electric signal of the numerical data output from the input part 12 has a sufficiently large magnitude.
- This cardiac oxygen consumption monitor unit 14 calculates the estimated value of cardiac oxygen consumption of the patient 20 through the following procedure.
- the cardiac oxygen consumption monitor unit 14 calculates the value of function of the systemic heart by using the following numerical formula (1) from the value of cardiac output and the value of pressure of left atrium input from the input part 12 .
- Value of function of systemic heart (Value of cardiac output)/ ⁇ Log((Value of pressure of left atrium) ⁇ A )+ B ⁇ (1) (wherein A and B denote constants)
- the A and B in this numerical formula (1) are the constants that are set in advance by the user. Incidentally, these constants are numerals that can be properly varied in accordance with the condition of the patient 20 . By having them adjusted in accordance with the condition of the patient 20 , the value of function of the systemic heart found by calculation can be compensated.
- the value of blood vessel resistance is calculated by using the following numerical formula (2) from the value of blood pressure, value of pressure of right atrium, and value of cardiac output input from the input part 12 .
- Value of blood vessel resistance ⁇ (Value of blood pressure) ⁇ (Value of pressure of right atrium) ⁇ H ) ⁇ /(Value of cardiac output)) (2) (wherein H denotes a constant)
- the H in this numerical formula (2) is the constant intended to compensate the nonlinearity of blood vessel resistance.
- this constant is a numeral that can be properly varied in accordance with the condition of the patient 20 .
- the slope of end-systolic pressure-volume relation is calculated by using the following numerical formula (3) from the value of function of systemic heart calculated by the numerical formula (1), the value of blood vessel resistance calculated by the numerical formula (2), and the heart rate input from the input part 12 .
- Slope of end-systolic pressure-volume relation (Value of function of systemic heart) ⁇ K ⁇ (Value of blood vessel resistance)/ ⁇ 1 ⁇ (Value of function of systemic heart) ⁇ K /Heart rate) ⁇ (3) (wherein K denotes a constant)
- the slope of end-systolic pressure-volume relation calculated by this numerical formula (3) represents the contraction characteristic of the ventricle in the unit of mmHg/ml.
- Pressure-volume area is calculated by using the following numerical formula (4) from the value of blood pressure, value of pressure of left atrium, value of cardiac output, and heart rate input from the input part 12 .
- Pressure-volume area (Value of blood pressure) ⁇ [ ⁇ Log ((Value of pressure of left atrium) ⁇ A )+ B ⁇ /K +(Value of cardiac output)/(Heart rate)]/2 (4) (wherein A, B, and K are as defined above)
- the constants A, B, and K in this numerical formula (4) are as described above.
- the pressure-volume area calculated by this numerical formula (4) represent the volume of work done in the unit of mmHg ⁇ ml.
- the estimated value of cardiac oxygen consumption is calculated by using the following numerical formula (5) from the heart rate input from the input part 12 , the pressure-volume area calculated by the numerical formula (4), and the slope of end-systolic pressure-volume relation calculated by the numerical formula (3).
- Amount of cardiac oxygen consumption (Heart rate) ⁇ (Pressure-volume area) ⁇ +(Slope of end-systolic pressure-volume relation) ⁇ + ⁇ (5) (wherein ⁇ , ⁇ , and ⁇ denote constants)
- This numerical formula (5) is based on the contents of the reference (“Prospective prediction of O 2 consumption from pressure volume area in dog hearts,” written by Suga, H in Am J Physiol. 1987; 252; H1258-64). According to this reference, the amount of cardiac oxygen consumption can be estimated from the pressure-volume area and the amount of cardiac oxygen consumption per minute can be calculated based on the numerical formula (5).
- the letters ⁇ , ⁇ , and ⁇ in the numerical formula (5) are constants that are set in advance by the user.
- the cardiac oxygen consumption monitor unit 14 is capable of rapidly calculating the estimated value of cardiac oxygen consumption by a simple operation because it calculates the value of function of systemic heart by using the aforementioned numerical formula (1) from the value of cardiac output and the value of pressure of left atrium, the value of blood vessel resistance by using the aforementioned numerical formula (2) from the value of blood pressure, the value of pressure of right atrium, and the value of cardiac output, the slope of end-systolic pressure-volume relation by using the aforementioned numerical formula (3) from the value of function of systemic heart, the value of blood vessel resistance, and the heart rate, the pressure-volume area by using the aforementioned numerical formula (4) from the value of blood pressure, the value of pressure of left atrium, the value of cardiac output, and the heart rate, and the estimated value of cardiac oxygen consumption by using the aforementioned numerical formula (5) from the heart rate, the pressure-volume area, and the slope of end-systolic pressure-volume relation.
- the inventor that owns the present invention has calculated the estimated value of cardiac oxygen consumption and as well measured the actual value of cardiac oxygen consumption by using this cardiac oxygen consumption monitor unit 14 and then compared the estimated value and the actually measured value of cardiac oxygen consumption.
- the actually measured value of cardiac oxygen consumption has been obtained by using the following numerical formula (6) after administering cardiac to dogs or constituting cardiac failure in dogs.
- Amount of cardiac oxygen consumption (Amount of blood flow through coronary artery) ⁇ (Oxygen content of arterial blood ⁇ Oxygen content of venous blood) (6)
- the amount of blood flow through the coronary artery (ml/min) in this numerical formula (6) has been measured with a blood flow meter mounted in the coronary artery under thoracotomy. Then, the oxygen content of arterial blood has been measured with an oxygen content meter using a sample of the arterial blood. Further, the oxygen content of venous blood has been measured with the oxygen content meter using a sample of the venous blood (of the heart) collected with a catheter inserted in the coronary venous sinus.
- FIG. 4 is a graph delineating the estimated value of the amount of cardiac oxygen consumption and the actually measured value of the amount of cardiac oxygen consumption found in dogs as calculated by using the cardiac oxygen consumption monitor unit 14 according to the present mode of embodiment.
- the cardiac disease treating system 10 according to the present mode of embodiment enables the amount of cardiac oxygen consumption to be easily estimated by adopting a measuring device used in an ordinary clinical scene and dismisses a fear that the patient may be exposed to a burden.
- the absolute values of the estimated value and the actually measured value in FIG. 4 do not perfectly agree. This fact may be explained by supposing that the numerical values of ⁇ , ⁇ , and ⁇ in the aforementioned numerical formula (5) vary among individuals. In fact, the question whether or not the estimated value can follow the relative change of the actually measured value is more important than the relation of these absolute values. In this respect, the estimated value of the cardiac oxygen consumption calculated by the cardiac oxygen consumption monitor unit 14 follows the change of the actually measured value. Thus, the lack of agreement between their absolute values does not pose any particular problem.
- FIG. 5 is a schematic diagram depicting the relation between the input part 12 and the cardiac oxygen consumption curtailment unit 16 in the cardiac disease treating system according to the present mode of embodiment.
- the cardiac oxygen consumption curtailment unit in the present mode of embodiment is composed of a computer 16 A for enabling the numerical data of heart rate measured by the electrocardiogram 12 C to be input therein via the amplifier 22 , a bradycardic medicine administration pump 16 B for administering a bradycardic medicine to the patient 20 , an atrium pacing device 16 C, and an atrium pacing catheter 16 D.
- This cardiac oxygen consumption curtailment unit 16 compares the heart rate input from the electrocardiogram 12 C and the critical heart rate (described in detail herein below) that minimizes the estimated value of the amount of cardiac oxygen consumption calculated by the cardiac oxygen consumption monitor unit 14 . Then, in accordance with the results of this comparison, the bradycardic medicine administration pump 16 B is used to administer the medicine to the patient 20 and, at the same time, the atrium pacing device 16 C and the atrium pacing catheter 16 D are used to impart electrical stimulation to the patient 20 .
- the present mode of embodiment is so constructed as to enable administration of the medicine by the bradycardic medicine administration pump 16 B and impartation of electrical stimulation by the atrium pacing device 16 C and the atrium pacing catheter 16 D.
- This invention nevertheless does not need to be limited to this construction.
- the cardiac oxygen consumption curtailment unit 16 may be furnished with only either of them.
- the method that controls the heart rate of the patient 20 by causing the cardiac oxygen consumption curtailment unit 16 to administer the medicine to the patient and/or impart the electrical stimulation to the patient 20 is simple procedurally and nevertheless enables the heart rate of the patient 20 to be rapidly and easily controlled.
- the heart rate of the patient 20 may be controlled by a method other than the method that relies on the administration of the medicine and the impartation of the electrical stimulation.
- the kind of medicine used for the administration to the patient 20 is not limited particularly.
- a ⁇ blocking agent, a calcium antagonist, a specific bradycardic agent, and the like may be administered.
- the cardiac disease treating system 10 for the purpose of solving this problem minimizes the patient's 20 cardiac oxygen consumption by lowering the heart rate and controlling it so as to approximate the critical heart rate by using the cardiac oxygen consumption curtailment unit 16 .
- the target value of function of systemic heart is found to be 34.8 ml/minute/kg and the target value of blood vessel resistance to be 0.9 mmHg ⁇ kg/ml in accordance with the aforementioned numerical formulas (1)-(5).
- K in the aforementioned numerical formula (7) is assumed to have a fixed value (0.0815), the slope of end-systolic pressure-volume relation (Ees) and the heart rate are correlated as shown in FIG. 6 in accordance with the numerical formula (7).
- the amount of cardiac oxygen consumption (VO 2 ) and the heart rate are correlated as shown in FIG. 7 in accordance with the aforementioned numerical formulas (1)-(5).
- the amount of cardiac oxygen consumption (VO 2 ) can be decreased as far as a prescribed heart rate B (“critical heart rate” according to this invention) in spite of an increase in the slope of end-systolic pressure-volume relation (Ees). That is, by performing the treatment so as to approximate the patient's 20 heart rate to the critical heart rate B, the patient's value of cardiac oxygen consumption can be decreased.
- the value of the critical heart rate B can be easily calculated by preparing a graph equivalent to FIG. 7 with respect to a relevant individual.
- the negative feedback control is so performed as to approximate the heart rate to the critical heart rate B by adjusting the amount of administration of the medicine to the patient 20 and the intensity and frequency of the electrical stimulation to the patient 20 thereby lowering the heart rate, though the method for this control is not particularly limited. Accordingly, the nonlinear control method that is based on the IF-THEN rule, for example, may be adopted or the linear control method that has recourse to proportionality, integral, differential, and the like may be adopted.
- the heart rate can be lowered still more efficiently by administering the medicine for bradycardia in a high dose at the start of treatment thereby controlling the spontaneous activity of the sinus node and, when the spontaneous activity appears, additionally administering the medicine for bradycardia thereby effecting the control so as to lower the heart rate stepwise.
- FIG. 8 is a schematic diagram of the cardiac disease treating unit 18 according to the present mode of embodiment.
- This cardiac disease treating unit 18 is composed of a calculation means 30 , a comparison means 40 , and an administration means 50 .
- This calculation means 30 is intended to perform a prescribed operation based on the indexes of kinetics of circulation input from the input part 12 and is composed of a first calculation means 31 , a second calculation means 32 , and a third calculation means 33 .
- the calculation means 30 may be formed of one calculation unit that collectively performs the operations of the first calculation means 31 , the second calculation means 32 , and the third calculation means 33 or it may be formed of three arithmetic units that severally perform the operations of the first calculation means 31 , the second calculation means 32 , and the third calculation means 33 .
- the first calculation means 31 calculates the value of function of systemic heart and the value of function of pulmonary heart from the value of cardiac output, the value of pressure of left atrium, and/or the value of pressure of right atrium that are input from the input part 12 .
- the second calculation means 32 calculates the value of amount of effectively circulated blood by using the following numerical formula (8) from the value of cardiac output, the value of pressure of left atrium, and the value of pressure of right atrium that are input from the input part 12 .
- the third calculation means 33 calculates the value of blood vessel resistance by using the numerical formula (2) or the numerical formula (7) from the value of cardiac output, the value of pressure of right atrium, and the value of blood pressure that are input from the input part 12 .
- the comparison means 40 is intended to compare the numerical values ⁇ numerical values of cardiac functions (value of function of systemic heart and/or value of function of pulmonary heart), value of amount of effectively circulated blood, and value of blood vessel resistance ⁇ calculated by the calculation means 30 and the target values (target values of functions of heart (target value of function of systemic heart and/or target value of function of pulmonary heart), target value of amount of effectively circulated blood, and target value of blood vessel resistance) and is composed of a first comparison means 41 , a second comparison means 42 , and a third comparison means 43 .
- the first comparison means 41 compares the value of function of systemic heart and/or the value of function of pulmonary heart that are calculated by the first calculation means 31 and the target values of functions of heart. Then, the second comparison means 42 compares the value of amount of effectively circulated blood calculated by the second calculation means 32 and the target value of amount of effectively circulated blood. Further, the third comparison means 43 compares the value of blood vessel resistance calculated by the third calculation means 33 and the target value of blood vessel resistance.
- first comparison means 41 can make three kinds of comparison that yield the calculated numerical values of “large,” “equal,” and “small” relative to the target value and transmit one of these three results of comparison as a signal of result of comparison to the administration means 50 , which will be described specifically herein below.
- the signals of the results of comparison are not limited to the three kinds of result of comparison “large,” “equal,” and “small.” They can transmit the signals that result from quantizing the calculated numerical values relative to the target value.
- the administration means 50 is intended to control the administration of a medicine to the patient 20 (adjustment of the dose) in conformity with the signal of the result of comparison from the comparison means 40 and is composed of a first administration means 51 , a second administration means 52 , and a third administration means 53 .
- This administration means 50 can allow application thereto of a multi-aperture catheter connected to a plurality of automatic injection pumps, for example, and used for simultaneous injection of a multitude of medicines. In this case, prescribed medicines are injected into the body of the patient 20 by having the multi-aperture catheter connected to the vein of the patient 20 .
- the administration of medicine by the first administration means 52 is carried out in conformity with the signal of result of comparison of the first comparison means 41 , the administration is fated to start when the abnormality of cardiac function is detected.
- the cardiac function is judged to be in an abnormal state and the first administration means 51 is caused to start the administration aimed at exalting the cardiac function.
- the medicine that is used in this case is a cardiac, which is specifically a dobutamine or dopamine, for example.
- the cardiac function is judged to be in a normal state and the first administration means is kept from increasing the dose or performing the administration or caused to stop the administration.
- the cardiac function is judged to be in a still better state than the target and the first administration means 51 is caused to decrease the dose, abstain from performing the administration, or stop the administration.
- the cardiac disease treating system 10 is composed of the first calculation means 31 for calculating the value of function of systemic heart and the value of function of pulmonary heart from the value of cardiac output, the value of pressure of left atrium, and the value of pressure of right atrium input from the input part 12 , the first comparison means 41 for comparing the value of function of systemic heart calculated by the cardiac oxygen consumption calculation monitor unit 14 and/or the value of function of systemic heart and the value of function of pulmonary heart calculated by the first calculation means 31 mentioned above and the target values of functions of heart, and the first administration means 51 for administering medicine to the patient 20 in conformity with the result of comparison emitted from the first comparison means 41 as described above and, therefore, is enabled to compare the values of functions of systemic and pulmonary hearts and the target values of cardiac function, perform the administration of medicine in conformity with the result of comparison, and infallibly and accurately cure the abnormal cardiac functions to the normal conditions.
- the administration of medicine by the second administration means 52 is implemented in conformity with the signal of result of comparison emitted from the second comparison means 42 , this administration is fated to start when abnormality is detected in the amount of effectively circulated blood.
- the second administration means 52 when the second administration means 52 has received the results of comparison “large” (as when the calculated value of amount of effectively circulated blood is higher than the target value of amount of effectively circulated blood, for example) from the second comparison means 42 , the amount of effectively circulated blood is judged to be in an abnormal state and the second administration means 52 is caused to start the administration of medicine intended to lower the amount of effectively circulated blood.
- the medicine that is used in this case is a diuretic, which is specifically furosemide.
- the second administration means 52 has received the result of comparison “equal” (as when the calculated value of amount of effectively circulated blood equals the target value of amount of effectively circulated blood, for example) from the second comparison means 42 , the amount of effectively circulated blood is judged to be in a normal state and the second administration means 52 is kept from increasing the dose or performing the administration or caused to stop the administration.
- the second administration means 52 has received the result of comparison “small” (as when the calculated value of amount of effectively circulated blood is lower than the target value of amount of effectively circulated blood, for example) from the second comparison means 42 , the amount of effectively circulated blood is judged to be in an abnormal state and the second administration means 52 is caused to start the administration aimed at increasing the amount of effectively circulated blood.
- the medicine that is administered in this case is a pharmaceutical preparation aimed at increasing the amount of effectively circulated blood, which is specifically a low molecular dextran or an albumin preparation, for example.
- the cardiac disease treating system 10 is composed of the second calculation means 32 for calculating the value of amount of effectively circulated blood from the value of cardiac output, the value of pressure of left atrium, and the value of pressure of right atrium input from the input part 12 , the second comparison means 42 for comparing the value of amount of effectively circulated blood calculated by the second calculation means 32 and the target value of amount of effectively circulated blood, and the second administration means 52 for administering a medicine to the patient 20 in conformity with the result of comparison emitted from the second comparison means 42 as described above and, therefore, is enabled to compare the calculated value of amount of effectively circulated blood and the target value of amount of effectively circulated blood, implement the administration of a medicine in conformity with the result of comparison, and infallibly and accurately cure the patient's abnormal amount of effectively circulated blood to the normal condition.
- the third administration means 53 when the third administration means 53 has received the result of comparison “large” (as when the calculated value of blood vessel resistance is higher than the target value of blood vessel resistance, for example) from the third comparison means 43 , the value of blood vessel resistance is judged to be in an abnormal state and the third administration means is caused to start the administration of a medicine intended to lower the value of blood vessel resistance.
- the medicine to be used in this case is a vasodilator, which is specifically nitroprusside, nitroglycerin, phentolamine, and the like, for example.
- the dose of vasoconstrictor is decreased when a vasoconstrictor such as, for example, norepinephrine has already been administered.
- the third administration means 53 has received the result of comparison “equal” (as when the calculated value of blood vessel resistance equals the target value of blood vessel resistance, for example) from the third comparison means 43 , the blood vessel resistance is judged to be in a normal state and the third administration means 53 is kept from increasing the dose and performing the administration or made to stop the administration.
- the third administration means 53 has received the result of comparison “small” (as when the calculated value of blood vessel resistance is lower than the target value of blood vessel resistance, for example) from the third comparison means 43 , the blood vessel resistance is judged to be in an abnormal state and the third administration means 53 is caused to start the administration of a medicine intended to raise the blood vessel resistance.
- the medicine to be used in this case is a vasoconstrictor, which is specifically norepinephrine, for example.
- the dose of vasodilator is decreased when a vasodilator such as, for example, nitroprusside, nitroglycerin, phentolamine, or the like has already been administered.
- the cardiac disease treating system 10 is composed of the third calculation means 33 for calculating the value of blood vessel resistance from the value of cardiac output, the value of pressure of right atrium, and the value of blood pressure input from the input part 12 , the third comparison means 43 for comparing the target value of blood vessel resistance, and the third administration means 53 for administering a medicine to the patient 20 in conformity with the result of comparison emitted from the third comparison means 43 as described above and, therefore, is enabled to compare the calculated value of blood vessel resistance and the target value of blood vessel resistance, perform the administration of a medicine in conformity with the result of this comparison, and infallibly and accurately cure the abnormal value of blood vessel resistance of the patent to the normal condition.
- the dosage of a medicine to be administered by the administration means 50 is not particularly limited but may be varied in accordance with the deflection of the calculated numerical value from the target value in the comparison means 40 , for example. By dividing the target value into a multitude of steps and adjusting the dosage of a medicine in accordance with each of these steps, it is made possible to perform the administration with very satisfactory accuracy.
- the inventor who owns the present invention has performed an experiment on the minimization of the amount of cardiac oxygen consumption by using the cardiac disease treating system 10 according to the present mode of embodiment.
- adult dogs in a state of cardiac failure have been used under anesthesia.
- the cardiac disease treating unit 18 has been used for controlling the dogs' kinetics of circulation (blood pressure, cardiac output, and pressure of left atrium) so as to make them assume a normal state and, at the same time, the cardiac oxygen consumption curtailment unit 16 has been used for controlling their heart rates by the administration of a specific bradycardic agent.
- the cardiac oxygen consumption curtailment unit 16 has been so controlled that, at the start of the treatment, the spontaneous activity of sinus node may be inhibited by the administration of a specific bradycardic agent in a high dose and, when the spontaneous activity appears, the specific bradycardic agent may be additionally administered to lower the heart rate stepwise.
- FIG. 9 The results of this experiment are shown in FIG. 9 .
- the dogs' blood pressures, cardiac outputs, and pressures of left atrium have been successfully maintained respectively near the target blood pressure, target cardiac output, and target pressure of left atrium.
- Their heart rates have lowered from about 160 beats/minute to about 110 beats/minute and neared 80 beats/minute, which is a critical heart rate.
- the cardiac disease treating system 10 when the cardiac disease treating system 10 is further furnished with a display means that continuously displays in time series the numerical values of the indexes of kinetics of circulation as illustrated in FIG. 9 mentioned above, it is enabled to diagnose a patient infallibly without any fear of overlooking the time series change in any of the numerical values and, at the same time, display the transition of the patient condition brought about by the treatment in the form of administration of a medicine.
- FIG. 10 shows the relation of the actually measured value of dogs' amount of cardiac oxygen consumption and the heart rate obtained in the present experiment. This experiment has resulted in successfully decreasing the dogs' amount of cardiac oxygen consumption by about 30% from about 3.5 ml O 2 /minute to about 2.4 ml O 2 /minute.
- the cardiac disease treating system 10 is capable of repressing (minimizing) the amount of cardiac oxygen consumption and preventing the occurrence of myocardiopathy because it is formed by incorporating therein a cardiac oxygen consumption automatic minimizing system that is composed of the input part 12 for inputting the patient's indexes of kinetics of circulation including at least heart rate, a cardiac oxygen consumption calculating part (the cardiac oxygen consumption monitor unit 14 in the present mode of embodiment) for calculating the estimated value of the patient's 20 amount of cardiac oxygen consumption based on the indexes of kinetics of circulation input from the input part 12 , and a cardiac oxygen consumption curtailing part (the cardiac oxygen consumption curtailment unit 16 in the present mode of embodiment) for comparing the heart rate input from the input part 12 and the critical heart rate B minimizing the estimated value of amount of cardiac oxygen consumption calculated by the cardiac
- cardiac disease treating system 10 is so constructed that it may be furnished with a cardiac disease treating unit 18 adapted to realize still further effectively the normalization of the patient's kinetics of circulation, this invention is not limited to this construction.
- the treatment may be given to a patient by using solely the cardiac oxygen consumption automatic minimization system that is composed of the input part, the cardiac oxygen consumption calculation part, and the cardiac oxygen consumption curtailment part, for example. Even in this case, the patient's amount of cardiac oxygen consumption can be estimated with high accuracy and the amount of cardiac oxygen consumption can be minimized. Further, the side effects of medicines used for the administration and the increase of therapeutic cost can be avoided and even a physician who is not a specialist can easily minimize the amount of cardiac oxygen consumption.
- the cardiac oxygen consumption automatic minimization system and the cardiac disease treating system according to this invention can be applied to the therapy of human beings, animals, and plants.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Public Health (AREA)
- Surgery (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Physiology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
- External Artificial Organs (AREA)
- Electrotherapy Devices (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Abstract
Description
[Mathematical 1]
Value of function of systemic heart=(Value of cardiac output)/{Log((Value of pressure of left atrium)−A)+B} (1)
(wherein A and B denote constants)
[Mathematical 2]
Value of blood vessel resistance={(Value of blood pressure)−(Value of pressure of right atrium)−H)}/(Value of cardiac output) (2)
(wherein H denotes a constant)
[Mathematical 3]
slope of end-systolic pressure-volume relation=(Value of function of systemic heart)×K×(Value of blood vessel resistance)/{1−(Value of function of systemic heart)×K/(Heart rate)} (3)
(wherein K denotes a constant)
[Mathematical 4]
pressure-volume area=(Value of blood pressure)×[{Log((Value of pressure of left atrium)−A)+B}/K+(Value of cardiac output)/(Heart rate)]/2 (4)
(wherein A, B, and K are as defined above)
[Mathematical 5]
Amount of cardiac oxygen consumption=(Heart rate)×[(pressure-volume area)×α+(slope of end-systolic pressure-volume relation)×β+γ] (5)
(wherein α, β, and γ denote constants).
[Mathematical 6]
Value of function of systemic heart=(Value of cardiac output)/{Log((Value of pressure of left atrium)−A)+B} (1)
(wherein A and B denote constants)
[Mathematical 7]
Value of blood vessel resistance={(Value of blood pressure)−(Value of pressure of right atrium)−H)}/(Value of cardiac output)) (2)
(wherein H denotes a constant)
[Mathematical 8]
Slope of end-systolic pressure-volume relation=(Value of function of systemic heart)×K×(Value of blood vessel resistance)/{1−(Value of function of systemic heart)×K/Heart rate)} (3)
(wherein K denotes a constant)
[Mathematical 9]
Pressure-volume area=(Value of blood pressure)×[{Log ((Value of pressure of left atrium)−A)+B}/K+(Value of cardiac output)/(Heart rate)]/2 (4)
(wherein A, B, and K are as defined above)
[Mathematical 10]
Amount of cardiac oxygen consumption=(Heart rate)×{(Pressure-volume area)×α+(Slope of end-systolic pressure-volume relation)×β+γ} (5)
(wherein α, β, and γ denote constants)
[Mathematical 11]
Amount of cardiac oxygen consumption=(Amount of blood flow through coronary artery)×(Oxygen content of arterial blood−Oxygen content of venous blood) (6)
[Mathematical 12]
Value of function of systemic heart=1/K×(Slope of end-systolic pressure-volume relation)/((Slope of end-systolic pressure-volume relation)/(Heart rate)+(Value of blood vessel resistance)) (7)
[Mathematical 13]
Value of amount of effectively circulated blood={(Value of cardiac output)+F×(Value of pressure of right atrium)+G×(Value of pressure of left atrium)}×E (8)
(wherein E, F, and G denote constants)
- 10 Cardiac disease treating system
- 12 Input part
- 14 Cardiac oxygen consumption monitor unit
- 16 Cardiac oxygen consumption curtailment unit
- 18 Cardiac disease treating unit
- 20 Patient
- 30 Calculation means
- 40 Comparison means
- 50 Administration means
Claims (12)
Value of function of systemic heart=(Value of cardiac output)/{Log((Value of pressure of left atrium)−A)+B},
Value of blood vessel resistance={(Value of blood pressure)−(Value of pressure of right atrium)−H)}/(Value of cardiac output),
slope of end-systolic pressure-volume relation=(Value of function of systemic heart)×K×(Value of blood vessel resistance)/{1−(Value of function of systemic heart)×K/(Heart rate)} (3)
Pressure-volume area=(Value of blood pressure)×[{Log((Value of pressure of left atrium)−A)+B}/K+(Value of cardiac output)/(Heart rate)]/2,
Amount of cardiac oxygen consumption=(Heart rate)×[(pressure-volume area)×α+(slope of end-systolic pressure-volume relation)×β+γ],
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006-038968 | 2006-02-16 | ||
JP2006038968A JP4581050B2 (en) | 2006-02-16 | 2006-02-16 | Cardiac oxygen consumption automatic minimization system and heart disease treatment system using the same |
PCT/JP2007/000096 WO2007094138A1 (en) | 2006-02-16 | 2007-02-16 | System for automatically minimizing cardiac oxygen consumption and cardiac disease treating system using the same |
Publications (2)
Publication Number | Publication Date |
---|---|
US20110098767A1 US20110098767A1 (en) | 2011-04-28 |
US8340749B2 true US8340749B2 (en) | 2012-12-25 |
Family
ID=38371326
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/279,753 Expired - Fee Related US8340749B2 (en) | 2006-02-16 | 2007-02-16 | System for automatically minimizing cardiac oxygen consumption and cardiac disease treating system using the same |
Country Status (3)
Country | Link |
---|---|
US (1) | US8340749B2 (en) |
JP (1) | JP4581050B2 (en) |
WO (1) | WO2007094138A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10054959B2 (en) | 2013-03-15 | 2018-08-21 | Bhushan Somani | Real time diagnostics for flow controller systems and methods |
US10983537B2 (en) | 2017-02-27 | 2021-04-20 | Flow Devices And Systems Inc. | Systems and methods for flow sensor back pressure adjustment for mass flow controller |
US11763947B2 (en) | 2020-10-14 | 2023-09-19 | Etiometry Inc. | System and method for providing clinical decision support |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130172774A1 (en) | 2011-07-01 | 2013-07-04 | Neuropace, Inc. | Systems and Methods for Assessing the Effectiveness of a Therapy Including a Drug Regimen Using an Implantable Medical Device |
WO2014081958A1 (en) * | 2012-11-21 | 2014-05-30 | Cardiomems, Inc. | Devices, systems, and methods for pulmonary arterial hypertension (pah) assessment and treatment |
US9198908B2 (en) | 2013-03-15 | 2015-12-01 | St. Jude Medical Luxembourg Holdings Ii S.A.R.L. (“Sjm Lux Ii”) | Methods for the treatment of cardiovascular conditions |
WO2017086294A1 (en) * | 2015-11-17 | 2017-05-26 | 国立大学法人東北大学 | Blood pressure estimation device, information processing device, blood pressure estimation method, and blood pressure estimation program |
US12053381B2 (en) | 2018-07-18 | 2024-08-06 | W. L. Gore & Associates, Inc. | Implantable medical device deployment system |
CN113490452A (en) * | 2018-12-21 | 2021-10-08 | W.L.戈尔及同仁股份有限公司 | Implantable cardiac sensor |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5024222A (en) | 1990-02-21 | 1991-06-18 | Siemens-Pacesetter, Inc. | Hemodynamically rate responsive pacemaker and method of automatically adjusting the escape and A-V intervals |
US5282839A (en) | 1992-12-14 | 1994-02-01 | Medtronic, Inc. | Rate responsive cardiac pacemaker and method for providing an optimized pacing rate which varies with a patient's physiologic demand |
US5749831A (en) * | 1997-06-23 | 1998-05-12 | Baker; Donald A. | Fetal cardiac monitoring utilizing umbilical blood flow parameters and heartbeat information |
JP2001104254A (en) | 1999-10-13 | 2001-04-17 | Sunnyhealth Co Ltd | Method for measuring dynamics of internal nutritive metabolism and device therefor |
US20040172074A1 (en) * | 2002-11-25 | 2004-09-02 | Terumo Kabushiki Kaisha | Heart treatment equipment for treating heart failure |
JP4218172B2 (en) | 2000-03-16 | 2009-02-04 | Jfeスチール株式会社 | Method for refining molten iron alloy |
-
2006
- 2006-02-16 JP JP2006038968A patent/JP4581050B2/en active Active
-
2007
- 2007-02-16 US US12/279,753 patent/US8340749B2/en not_active Expired - Fee Related
- 2007-02-16 WO PCT/JP2007/000096 patent/WO2007094138A1/en active Application Filing
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5024222A (en) | 1990-02-21 | 1991-06-18 | Siemens-Pacesetter, Inc. | Hemodynamically rate responsive pacemaker and method of automatically adjusting the escape and A-V intervals |
JPH04218172A (en) | 1990-02-21 | 1992-08-07 | Siemens Ag | Heart output optimizer |
US5282839A (en) | 1992-12-14 | 1994-02-01 | Medtronic, Inc. | Rate responsive cardiac pacemaker and method for providing an optimized pacing rate which varies with a patient's physiologic demand |
JPH06511418A (en) | 1992-12-14 | 1994-12-22 | メドトロニック インコーポレーテッド | Rate-responsive cardiac pacemaker that provides an optimized pacing rate that varies with the patient's physiological demands |
US5749831A (en) * | 1997-06-23 | 1998-05-12 | Baker; Donald A. | Fetal cardiac monitoring utilizing umbilical blood flow parameters and heartbeat information |
JP2001104254A (en) | 1999-10-13 | 2001-04-17 | Sunnyhealth Co Ltd | Method for measuring dynamics of internal nutritive metabolism and device therefor |
JP4218172B2 (en) | 2000-03-16 | 2009-02-04 | Jfeスチール株式会社 | Method for refining molten iron alloy |
US20040172074A1 (en) * | 2002-11-25 | 2004-09-02 | Terumo Kabushiki Kaisha | Heart treatment equipment for treating heart failure |
Non-Patent Citations (2)
Title |
---|
International Search Report issued in corresponding application PCT/JP2007/000096, completed Mar. 9, 2007 and mailed Mar. 20, 2007. |
Suga, H. et al. "Prospective prediction of O2 consumption from pressure volume area in dog hearts," Am J Physiol. 1987; 252; H1258-64. |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10054959B2 (en) | 2013-03-15 | 2018-08-21 | Bhushan Somani | Real time diagnostics for flow controller systems and methods |
US10983537B2 (en) | 2017-02-27 | 2021-04-20 | Flow Devices And Systems Inc. | Systems and methods for flow sensor back pressure adjustment for mass flow controller |
US10983538B2 (en) | 2017-02-27 | 2021-04-20 | Flow Devices And Systems Inc. | Systems and methods for flow sensor back pressure adjustment for mass flow controller |
US11300983B2 (en) | 2017-02-27 | 2022-04-12 | Flow Devices And Systems Inc. | Systems and methods for flow sensor back pressure adjustment for mass flow controller |
US11763947B2 (en) | 2020-10-14 | 2023-09-19 | Etiometry Inc. | System and method for providing clinical decision support |
Also Published As
Publication number | Publication date |
---|---|
JP4581050B2 (en) | 2010-11-17 |
US20110098767A1 (en) | 2011-04-28 |
WO2007094138A1 (en) | 2007-08-23 |
JP2007215724A (en) | 2007-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8340749B2 (en) | System for automatically minimizing cardiac oxygen consumption and cardiac disease treating system using the same | |
US9943236B2 (en) | Methods for guiding heart failure decompensation therapy | |
US10709341B2 (en) | Devices, systems, and methods for pulmonary arterial hypertension (PAH) assessment and treatment | |
Rinehart et al. | First closed-loop goal directed fluid therapy during surgery: a pilot study | |
EP4026490A1 (en) | Method and apparatus for prediction of fluid responsiveness in mechanically ventilated subjects | |
JP2001204817A (en) | System for extrapolation of glucose concentration | |
US11547341B2 (en) | Non-invasive system and method for monitoring lusitropic myocardial function in relation to inotropic myocardial function | |
US9950175B2 (en) | Remote closed-loop titration of decongestive therapy for the treatment of advanced heart failure | |
WO2016196080A1 (en) | Multi-sensor volume index | |
JP2007215724A5 (en) | ||
US11284836B2 (en) | Methods and systems for improved prediction of fluid responsiveness | |
Uemura et al. | Less invasive and inotrope-reduction approach to automated closed-loop control of hemodynamics in decompensated heart failure | |
WO2020243658A1 (en) | Real-time methods to enable precision-guided cpr to improve neurological outcome and predict brain damage | |
JP4892667B2 (en) | Heart disease treatment system | |
US20030226568A1 (en) | Resuscitation from shock | |
Paranjape et al. | Agreement of cardiac output measurements by esophageal Doppler and transesophageal echocardiography with intermittent pulmonary artery thermodilution during pharmacologic manipulation of hemodynamics in anesthetized dogs | |
Aritürk et al. | Is the Nexfin finger cuff method for cardiac output measurement reliableduring coronary artery bypass grafting? A prospective comparison with the echocardiography and FloTrac/Vigileo methods | |
Bailey et al. | Closed-loop control in clinical pharmacology paradigms, benefits, and challenges | |
US20050123579A1 (en) | System for treating heart disease and cardiovascular disease in diabetic and non-diabetic patients | |
Arpaia et al. | Insulin Absorption Assessment Based on Bioimpedance Measurements: Model optimization for Improving Accuracy in Clinical Application | |
US20230355871A1 (en) | Minimally Invasive and Semi-Automated Myocardial Injection Device | |
RU2373960C2 (en) | System for cardiopathy treatment | |
Ervan Zuhri et al. | Case Report Management of Diabetic Ketoacidosis Concomitant With Acute Myocardial Infarction With Acute Heart Failure: A Case Report | |
Bernabeu Santisteban | Staggered passive leg raising test for predicting several degrees of fluid responsiveness in mechanical ventilated patients: an observational study | |
JP2014512368A (en) | Preoperative use of metabolic activation therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: FUJIKIN INCORPORATED, JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SUGIMACHI, MASARU;UEMURA, KAZUNORI;KAMIYA, ATSUNORI;AND OTHERS;SIGNING DATES FROM 20080808 TO 20080815;REEL/FRAME:021402/0331 Owner name: JAPAN HEALTH SCIENCES FOUNDATION, JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SUGIMACHI, MASARU;UEMURA, KAZUNORI;KAMIYA, ATSUNORI;AND OTHERS;SIGNING DATES FROM 20080808 TO 20080815;REEL/FRAME:021402/0331 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
REMI | Maintenance fee reminder mailed | ||
FPAY | Fee payment |
Year of fee payment: 4 |
|
SULP | Surcharge for late payment | ||
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
FEPP | Fee payment procedure |
Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
LAPS | Lapse for failure to pay maintenance fees |
Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20201225 |